Table 1 Patient characteristics
Characteristic | N = 562 |
|---|---|
Age in years, mean (SD) | 50.5 (9.8) |
Median | 50.5 |
Minimum, maximum | 23.7, 79.2 |
Age group, n (%) | |
18–34 | 30 (5.3%) |
35–44 | 128 (22.8%) |
45–54 | 229 (40.7%) |
55–64 | 137 (24.4%) |
65+ | 38 (6.8%) |
Female, n (%) | 352 (62.6%) |
Index year, n (%) | |
2011 | 185 (32.9%) |
2012 | 265 (47.2%) |
2013 | 112 (19.9%) |
MS ICD-10-GM codes at index quarter, n (%)a | |
G35.0: Initial manifestation of MS | 92 (16.4%) |
G35.1: Mainly relapsing/remitting MS | 288 (51.2%) |
G35.2: Primary progressive MS | 121 (21.5%) |
G35.3: Secondary progressive MS | 175 (31.1%) |
G35.9: MS, unspecified | 450 (80.1%) |
Exclusively unspecified diagnosis (G35.9) | 85 (15.1%) |
First prescribed DMT, n (%)c | |
IM INF beta-1a | 50 (8.9%) |
SC INF beta-1a | 48 (8.5%) |
SC INF beta-1b | 59 (10.5%) |
Glatiramer acetate | 85 (15.1%) |
Natalizumab | 41 (7.3%) |
Teriflunomide | 0 (0%) |
Fingolimod | 19 (3.4%) |
Dimethyl fumarate | 3 (0.5%) |
None | 257 (45.7%) |
MS-related medications, n (%)d | |
Corticosteroids | 225 (40.0%) |
Immunosuppressants | 84 (14.9%) |
Drugs for symptom relief, n (%)d | |
Antidementia | 6 (1.1%) |
Antidepressants | 179 (31.9%) |
Antiepileptics | 97 (17.3%) |
Select muscle relaxants | 227 (40.4%) |
Urinary antispasmodics | 122 (21.7%) |
Medications to manage fatigue | 37 (6.6%) |
Medications for tremor | 2 (0.4%) |
CCI, mean (SD)d | 1.08 (1.39) |
Median | 0 |
Minimum, maximum | 0.00, 6.00 |
CCI, n (%)d | |
0 | 210 (37.4%) |
1 | 61 (10.9%) |
2+ | 291 (51.8%) |
Top 10 diagnoses using ICD-10-GM codes (n, %)d | |
H52.2: Astigmatism | 158 (28.1%) |
I10.9: Essential (primary) hypertension not further specified | 123 (21.9%) |
F32.9: Depressive episode unspecified | 122 (21.7%) |
G82.4: Spastic tetraplegia | 113 (20.1%) |
H52.4: Presbyopia | 107 (19.0%) |
R26.8: Other and unspecified abnormalities of gait and mobility | 107 (19.0%) |
N31.9: Neuromuscular dysfunction of bladder unspecified | 101 (18.0%) |
N89.8: Other specified non-inflammatory disorders of vaginab | 100 (28.4%) |
N39.4: Other specified urinary incontinence | 99 (17.6%) |
G82.1: Spastic paraplegia | 98 (17.4%) |